Comparison of two hormone replacement regimens — influence on lipoproteins and bone mineral content

Two hormone replacement therapy regimens were tested in a double-blind clinical trial involving 49 patients and both proved to be equally effective in alleviating climacteric complaints, but the low-density-lipoprotein cholesterol lowering effect of SH D 461 A was found to be superior to that of Cyclo-Progynova.

Abstract

Two hormone replacement therapy regimens were tested in a double-blind clinical trial involving 49 patients. In both cases the oestrogen component was 2 mg oestradiol valerate. This was administered for 21 days and sequentially combined for 10 days with either 0.5 mg norgestrel (Cyclo-Progynova) or 1 mg cyproterone acetate (SH D 461 A). Each treatment cycle was followed by a 7-day tablet-free period. Both regimens proved to be equally effective in alleviating climacteric complaints. However, the low-density-lipoprotein cholesterol lowering effect of SHD 461 A was found to be superior to that of Cyclo-Progynova®. There were no changes in bone mineral content during the one-year treatment period with either combination.